Given these implications, germline SMARCA4 testing and cascade screening of at-risk relatives are essential to enable tailored surveillance strategies, including periodic imaging and biochemical assessments for early tumor detection and improved clinical outcomes. Here, SMARCA4 is linked to neoplasm.